New to this stock and just doing some research. In the short term afamelanotide looks to be aimed at some acute disorders which are extremely rare. Is this a profitable market? Are they really looking at the cosmetic market? If the latter I imagine theres a few more regulatory hurdles to go post therapeutic approval?
Can anyone comment?
target market
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
-0.430(3.17%) |
Mkt cap ! $665.5M | |||
| Open | High | Low | Value | Volume |
| $13.46 | $13.57 | $13.13 | $534.0K | 40.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 696 | $13.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 165 | 4 |
View Market Depth
| Last trade - 12.49pm 22/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |